Press Release #1 summarizes the central points of the RVx Website, which lay out a vision of how the diagnosis, clinical management, and prevention of recurrent herpetic diseases, such as genital herpes, may radically improve with the introduction of three new technologies:
(1) RVx’s two new vaccine technologies, Theravax and Profavax, work about 100-fold better than the herpes subunit vaccine concepts (i.e., theoretical garbage) that have been the sole focus of U.S. herpes vaccine trials between 1985 and 2016, and which are clearly too weak to do the job.
(2) the HSV ABVIC Test, which is about 100-fold more sensitive and far less prone to false-positive results than the herpes serology tests of the past 20 years that get a D-rating from the U.S. Preventative Services Task Force . A D-rating means, “Doctors, you should avoid these error-prone herpes serology tests like the plague. Do not use them under any circumstances.”
It’s time for the medical community to quit going through the motions of pretending like we are doing a good job diagnosing, treating and preventing herpetic disease. The new technologies that RVx is offering will, finally, provide doctors with 100-fold more powerful tools that allow them to, for real, (1) accurately diagnose, (2) better manage, and (3) effectively prevent all forms of herpetic disease.